BMS Buys Land for New Biologics Facility

Bristol-Myers Squibb has completed the land purchase of an 89-acre site from MassDevelopment for its new large-scale multi-product bulk biologics manufacturing facility in Devens, MA. The two companies have also finalized agreements related to the facility’s utility infrastructure, including waste water treatment, use of electricity, water, and natural gas. Construction on the facility is expected to begin in the next several weeks, and is projected to be operational in 2009. The company plans to submit the site for regulatory approval in 2010.

The new facility is expected to support increased production capacity for biologic compounds, such as Orencia, and help meet future production needs of compounds currently in development, including investigational treatments for solid organ transplant rejection and certain types of cancers.